Iovance Biotherapeutics, Inc.
IOVA
$3.78
-$0.10-2.58%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 44.82% | 17.74% | 15.20% | 92.73% | 6,798.46% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.82% | 17.74% | 15.20% | 92.73% | 6,798.46% |
| Cost of Revenue | -0.51% | 14.08% | 22.08% | 80.64% | 488.28% |
| Gross Profit | 337.77% | 21.60% | 7.18% | 1,354.96% | 200.96% |
| SG&A Expenses | -11.08% | -13.99% | -12.15% | -4.72% | 39.52% |
| Depreciation & Amortization | 5.88% | 3.98% | -7.44% | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.60% | -0.02% | 6.50% | 30.60% | 44.00% |
| Operating Income | 33.14% | 15.15% | -0.78% | -11.64% | -2.97% |
| Income Before Tax | 32.45% | 6.86% | -10.11% | -11.27% | -3.16% |
| Income Tax Expenses | 63.82% | -88.19% | -58.22% | 236.35% | -30.54% |
| Earnings from Continuing Operations | 31.95% | 8.47% | -9.23% | -14.99% | -2.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.95% | 8.47% | -9.23% | -14.99% | -2.82% |
| EBIT | 33.14% | 15.15% | -0.78% | -11.64% | -2.97% |
| EBITDA | 35.93% | 12.46% | 0.62% | -12.06% | -2.77% |
| EPS Basic | 47.50% | 31.43% | 9.00% | 2.08% | 15.22% |
| Normalized Basic EPS | 48.11% | 35.81% | 13.29% | 5.27% | 15.11% |
| EPS Diluted | 47.50% | 31.43% | 9.00% | 2.08% | 15.22% |
| Normalized Diluted EPS | 48.11% | 35.81% | 13.29% | 5.27% | 15.11% |
| Average Basic Shares Outstanding | 29.62% | 33.48% | 20.04% | 17.45% | 21.28% |
| Average Diluted Shares Outstanding | 29.62% | 33.48% | 20.04% | 17.45% | 21.28% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |